Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Aspirin (niedrig dosiert) – Forschungsarchiv – Seite 21 von 60 | SupStack

Aspirin (niedrig dosiert) – Forschungsarchiv

Studien 1951–2000 von 3914, neueste zuerst

Die 1000 neuesten Studien – mit Evidenz-Zusammenfassung, Filtern und Suche – stehen auf der Hauptseite. Dieses Archiv listet die übrigen, 50 pro Seite. Zurück zur Hauptseite

1951RCT2008

Gao L, Li YJ, Chen KY · Zhongguo Zhong Xi Yi Jie He Za Zhi (2008)

Für dieses Zitat ist keine Zusammenfassung hinterlegt — öffne die Arbeit, um das Abstract zu lesen.

1952RCT2008

Persell SD, Denecke-Dattalo TA, Dunham DP, Baker DW · Jt Comm J Qual Patient Saf (2008)

Für dieses Zitat ist keine Zusammenfassung hinterlegt — öffne die Arbeit, um das Abstract zu lesen.

Aspirin (niedrig dosiert) – Forschungsarchiv

[Effects of supplementing qi and activating blood circulation method on platelet aggregation rate, adhesion rate and thromboxane B2 level in patients with stable angina pectoris and intolerable to aspirin].

Patient-directed intervention versus clinician reminders alone to improve aspirin use in diabetes: a cluster randomized trial.

Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis.

Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial.

Aspirin use and post-operative bleeding from dental extractions.

Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review.

Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis.

[Aspirin resistance].

Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design.

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.

Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial.

Selenium and aspirin in people living with HIV and AIDS in Nigeria.

Inhibition of platelet aggregation by combined therapy with aspirin and cilostazol after off-pump coronary artery bypass surgery.

Bleeding time prolonged by daily low-dose aspirin is shortened by one medium dose aspirin.

Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo-controlled crossover trial.

Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.

Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) Trial: rationale and design.

Platelet activity and aspirin efficacy after off-pump compared with on-pump coronary artery bypass surgery: results from the prospective randomized trial PRAGUE 11-Coronary Artery Bypass and REactivity of Thrombocytes (CABARET).

The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies.

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.

Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome.

Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range.

Randomised aspirin assignment and risk of adult-onset asthma in the Women's Health Study.

Oral anticoagulation after myocardial infarction.

Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects.

[Clinical value of protoparaxotril saporlirs combined with aspirin in the secondary prevention of cerebral infarction].

Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial.

[Effects of puerarin with aspirin on the markers of damaged vascular endothelial cells in patients with acute cerebral infarction].

Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.

Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005.

Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial.

Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial.

Aspirin for the primary prevention of adverse cardiovascular events.

The effects of aspirin and nonselective beta blockade on the acute prothrombotic response to psychosocial stress in apparently healthy subjects.

[Correction of the disturbed coagulation circadian rhythm in patients with type 1 diabetes mellitus treated by aspirin chronotherapy].

Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin.

Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events.

Effect of clopidogrel on adhesion molecules, hemostasis, and fibrinolysis in coronary heart disease.

Safety of triflusal (antiplatelet drug) in patients with aspirin-exacerbated respiratory diseases.

Effect of aspirin on airway inflammation and pulmonary function in patients with persistent asthma.

The effect of high-dose aspirin pre-treatment on the incidence of myonecrosis following elective coronary stenting.

Characterization of total plasma glycosaminoglycan levels in healthy volunteers following oral administration of a novel antithrombotic odiparcil with aspirin or enoxaparin.

Magnitude and time course of platelet inhibition with extended release dipyridamole with or without aspirin in healthy Japanese volunteers. The AGgrenox versus Aspirin Therapy Evaluation (AGATE-Japan).

[A clinical trial of using antiplatelet therapy to prevent restenosis following peripheral artery angioplasty and stenting].

Vitamins B2, B6, and B12 and risk of new colorectal adenomas in a randomized trial of aspirin use and folic acid supplementation.

Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events--a meta-analysis.

The role of clopidogrel and acetylsalicylic acid in the prevention of early-phase graft occlusion due to reactive thrombocytosis after coronary artery bypass operation.

Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients.

Lack of interference of aspirin in HbA1c measured by ion-exchange HPLC in type 2 diabetic patients: a randomized, double-blind, placebo-controlled study.

The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.